Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Study protocol

Study protocol of the CORRECT multicenter trial: the efficacy of blended cognitive behavioral therapy for reducing psychological distress in colorectal cancer survivors

Authors: L. Leermakers, S. Döking, B. Thewes, A. M. J. Braamse, M. F. M. Gielissen, J. H. W. de Wilt, E. H. Collette, J. Dekker, J. B. Prins

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Approximately one third of the colorectal cancer survivors (CRCS) experience high levels of psychological distress. Common concerns experienced by CRCS include distress related to physical problems, anxiety, fear of cancer recurrence (FCR) and depressive symptoms. However, psychological interventions for distressed CRCS are scarce. Therefore, a blended therapy was developed, combining face-to-face cognitive behavioral therapy (CBT) with online self-management activities and telephone consultations. The aim of the study is to evaluate the efficacy and cost-effectiveness of this blended therapy in reducing psychological distress in CRCS.

Methods/design

The CORRECT study is a two-arm multicenter randomized controlled trial (RCT). A sample of 160 highly distressed CRCS (a score on the Distress Thermometer of 5 or higher) will be recruited from several hospitals in the Netherlands. CRCS will be randomized to either the intervention condition (blended CBT) or the control condition (care as usual). The blended therapy covers approximately 14 weeks and combines five face-to-face sessions and three telephone consultations with a psychologist, with access to an interactive self-management website. It includes three modules which are individually-tailored to patient concerns and aimed at decreasing: 1) distress caused by physical consequences of CRC, 2) anxiety and FCR, 3) depressive symptoms. Patients can choose between the optional modules. The primary outcome is general distress (Brief Symptom Inventory-18). Secondary outcomes are quality of life and general psychological wellbeing. Assessments will take place at baseline prior to randomization, after 4 and 7 months.

Discussion

Blended CBT is an innovative and promising approach for providing tailored supportive care to reduce high distress in CRCS. If the intervention proves to be effective, an evidence-based intervention will become available for implementation in clinical practice.

Trial registration

This trial is registered in the Netherlands Trial Register (NTR6025) on August 3, 2016.
Literature
1.
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.CrossRefPubMed
2.
Mosher CE, Winger JG, Given BA, Helft PR, O'Neil BH. Mental health outcomes during colorectal cancer survivorship: a review of the literature. Psycho-Oncology. 2016;25(11):1261–70.CrossRefPubMed
3.
4.
Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.CrossRefPubMed
5.
Dunn J, Ng SK, Holland J, Aitken J, Youl P, Baade PD, Chambers SK. Trajectories of psychological distress after colorectal cancer. Psycho-Oncology. 2013;22(8):1759–65.CrossRefPubMed
6.
Lynch BM, Steginga SK, Hawkes AL, Pakenham KI, Dunn J. Describing and predicting psychological distress after colorectal cancer. Cancer. 2008;112(6):1363–70.CrossRefPubMed
7.
Steginga SK, Lynch BM, Hawkes A, Dunn J, Aitken J. Antecedents of domain-specific quality of life after colorectal cancer. Psychooncology. 2009;18(2):216–20.CrossRefPubMed
8.
Jansen L, Koch L, Brenner H, Arndt V. Quality of life among long-term (>/=5 years) colorectal cancer survivors--systematic review. Eur J Cancer. 2010;46(16):2879–88.CrossRefPubMed
9.
Thong MS, Mols F, Wang XS, Lemmens VE, Smilde TJ, van de Poll-Franse LV. Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer. 2013;49(8):1957–66.CrossRefPubMedCentralPubMed
10.
Husson O, Mols F, van de Poll-Franse LV, Thong MS. The course of fatigue and its correlates in colorectal cancer survivors: a prospective cohort study of the PROFILES registry. Support Care Cancer. 2015;23(11):3361–71.CrossRefPubMedCentralPubMed
11.
van de Beuken- van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–49.CrossRef
12.
Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 2009;48(6):832–41.CrossRefPubMed
13.
Phipps E, Braitman LE, Stites S, Leighton JC. Quality of life and symptom attribution in long-term colon cancer survivors. J Eval Clin Pract. 2008;14(2):254–8.CrossRefPubMed
14.
Sprangers MA, Taal BG, Aaronson NK, te Velde A. Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum. 1995;38(4):361–9.CrossRefPubMed
15.
Schneider EC, Malin JL, Kahn KL, Ko CY, Adams J, Epstein AM. Surviving colorectal cancer - patient-reported symptoms 4 years after diagnosis. Cancer. 2007;110(9):2075–82.CrossRefPubMed
16.
Vonk-Klaassen SM, de Vocht HM, den Ouden ME, Eddes EH, Schuurmans MJ. Ostomy-related problems and their impact on quality of life of colorectal cancer ostomates: a systematic review. Qual Life Res. 2016;25(1):125–33.CrossRefPubMed
17.
Orsini RG, Vermeer TA, Traa MJ, Nieuwenhuijzen GA, de Hingh IH, Rutten HJ. Does extended surgery influence health-related quality of life in patients with rectal cancer? Dis Colon Rectum. 2015;58(2):179–85.CrossRefPubMed
18.
Traa MJ, De Vries J, Roukema JA, Den Oudsten BL. Sexual (dys)function and the quality of sexual life in patients with colorectal cancer: a systematic review. Ann Oncol. 2012;23(1):19–27.CrossRefPubMed
19.
Sehlo MG, Al Ahwal MS. Depression in patients with colorectal cancer. Saudi Med J. 2013;34(4):341–7.PubMed
20.
Medeiros M, Oshima CT, Forones NM. Depression and anxiety in colorectal cancer patients. J Gastrointest Cancer. 2010;41(3):179–84.CrossRefPubMed
21.
Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, de Groot GH, van der Hulst RW, Klemt-Kropp M, Kuiken SD, Loffeld RJ, Uiterwaal MT, Mulder CJ, et al. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. Eur J Gastroenterol Hepatol. 2016;28(7):831–5.CrossRefPubMed
22.
Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, Dinkel A, Butow P. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016;24(8):3265–8.CrossRefPubMed
23.
Fisher A, Beeken RJ, Heinrich M, Williams K, Wardle J. Health behaviours and fear of cancer recurrence in 10 969 colorectal cancer (CRC) patients. Psycho-Oncology. 2016;25(12):1434–40.CrossRefPubMedCentralPubMed
24.
Custers JA, Gielissen MF, Janssen SH, de Wilt JH, Prins JB. Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer. 2016;24(2):555–62.CrossRefPubMed
25.
Faller H, Schuler M, Richard M, Heckl U, Wies J, Küffner R. Effects of psycho-oncological interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31(8):782–93.CrossRefPubMed
26.
Mosher CE, Winger JG, Given BA, Shahda S, Helft PR. A systematic review of psychosocial interventions for colorectal cancer patients. Support Care Cancer. 2017;25(7):2349–62.CrossRefPubMedCentralPubMed
27.
Lepore SJ, Revenson TA, Roberts KJ, Pranikoff JR, Davey A. Randomised controlled trial of expressive writing and quality of life in men and women treated for colon or rectal cancer. Psychol Health. 2015;30(3):284–300.CrossRefPubMed
28.
Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, et al. A randomized controlled trial of a nurse-led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist. 2016;21(8):1014–23.CrossRefPubMedCentralPubMed
29.
White VM, Macvean ML, Grogan S, D'Este C, Akkerman D, Ieropoli S, Hill DJ, Sanson-Fisher R. Can a tailored telephone intervention delivered by volunteers reduce the supportive care needs, anxiety and depression of people with colorectal cancer? A randomised controlled trial. Psychooncology. 2012;21(10):1053–62.CrossRefPubMed
30.
Hawkes AL, Pakenham KI, Chambers SK, Patrao TA, Courneya KS. zEffects of a multiple health behavior change intervention for colorectal cancer survivors on psychosocial outcomes and quality of life: a randomized controlled trial. Ann Behav Med. 2014;48(3):359–70.CrossRefPubMed
31.
Spek V, et al. Internet-based cognitive behaviour therapy for symptoms of depression and anxiety: a meta-analysis. Psychol Med. 2007;37(3):319–28.CrossRefPubMed
32.
Palmqvist B, Carlbring P, Andersson G. Internet-delivered treatments with or without therapist input: does the therapist factor have implications for efficacy and cost? Expert Rev Pharmacoecon Outcomes Res. 2007;7(3):291–7.CrossRefPubMed
33.
Andersson G, Cuijpers P, Carlbring P, Riper H, Hedman E. Guided internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry. 2014;13(3):288–95.CrossRefPubMedCentralPubMed
34.
van Beugen S, Ferwerda M, Hoeve D, Rovers MM, Spillekom-van Koulil S, van Middendorp H, Evers AW. Internet-based cognitive behavioral therapy for patients with chronic somatic conditions: a meta-analytic review. J Med Internet Res. 2014;16(3):e88.CrossRefPubMedCentralPubMed
35.
Leykin Y, Thekdi SM, Shumay DM, Munoz RF, Riba M, Dunn LB. Internet interventions for improving psychological well-being in psycho-oncology: review and recommendations. Psychooncology. 2012;21(9):1016–25.CrossRefPubMed
36.
Schulz KF, Altman DG, Mohrer D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Br Med J (Clin Res Ed). 2010;340:698–702.CrossRef
37.
Baker TB, Gustafson DH, Shaw B, Hawkins R, Pingree S, Roberts L, Strecher V. Relevance of CONSORT reporting criteria for research on eHealth interventions. Patient Educ Couns. 2010;81:77–86.CrossRef
38.
Rehse B, Pukrop R. Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies. Patient Educ Couns. 2003;50(2):179–86.CrossRefPubMed
39.
Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med. 2006;29(1):17–27.CrossRefPubMed
40.
Meyer TJ, Mark MM. Effects of psychosocial inerventions with adult cancer patiens: a meta-analysis of randomized experiments. Health Psychol. 1995;14(2):101–8.CrossRefPubMed
41.
Schneider S, Moyer A, Knapp-Oliver S, Sohl S, Cannella D, Targhetta V. Pre-intervention distress moderates the efficacy of psychosocial treatment for cancer patients: a meta-analysis. J Behav Med. 2010;33(1):1–14.CrossRefPubMed
42.
Beck JS, Beck AT. Cognitive behavior therapy. Second edition: basics and beyond. New York: The Guilford Press; 2011.
43.
Ritterband LM, Thorndike FP, Cox DJ, Kovatchev BP, Gonder-Frederick LA. A behavior change model for internet interventions. Ann Behav Med. 2009;38(1):18–27.CrossRefPubMed
44.
Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (Clinical Research Ed). 2014;348:g1687.
45.
van den Berg SW, Gielissen MF, Ottevanger PB, Prins JB. Rationale of the BREAst cancer e-healTH [BREATH] multicentre randomised controlled trial: an internet-based self-management intervention to foster adjustment after curative breast cancer by decreasing distress and increasing empowerment. BMC Cancer. 2012;12:394.CrossRefPubMedCentralPubMed
46.
van de Wal MA, Gielissen MF, Servaes P, Knoop H, Speckens AE, Prins JB. Study protocol of the SWORD-study: a randomised controlled trial comparing combined online and face-to-face cognitive behaviour therapy versus treatment as usual in managing fear of cancer recurrence. BMC Psychology. 2015;3(1):12.CrossRefPubMedCentralPubMed
47.
van den Berg SW, Gielissen MFM, Custers JAE, van der Graaf WTA, Ottevanger PB, Prins JB. BREATH: web-based self-Management for Psychological Adjustment after primary breast cancer - results of a multicenter randomized controlled trial. J Clin Oncol. 2015;33:2763–71.CrossRefPubMed
48.
Custers JAE, Gielissen MFM, de Wilt JHW, Prins JB. Fear of cancer recurrence, quality of life and distress in the first year afther the diagnosis of colorectal cancer. Psychooncology. 2015;24(Suppl. 2):91.
49.
Jaspers MWM. A comparison of usability methods for testing interactive health technologies: methodological aspects and empirical evidence. Int J Med Inform. 2009;78:340–53.CrossRefPubMed
50.
Brooke J. SUS: a “quick and dirty” usability scale. In: Jordan PW, Thomas B, Weerdmeester A, McClelland IL, editors. Usability evaluation in industry. London: Taylor & Francis; 1996. p. 189–94.
51.
Bangor A, Kortum PT, Miller JT. An empirical evaluation of the system usability scale. Int J Hum Comput Interact. 2008;24(6):574–94.CrossRef
52.
Peters JB, Daudey L, Heijdra YF, Molema J, Dekhuijzen PN, Vercoulen JH. Development of a battery of instruments for detailed measurement of health status in patients with COPD in routine care: the Nijmegen clinical screening instrument. Qual Life Res. 2009;18(7):901–12.CrossRefPubMedCentralPubMed
53.
van de Wal MA, Thewes B, Gielissen MFM, Speckens AE, Prins JB. Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal cancer survivors; the SWORD-study, a randomized controlled trial. J Clin Oncol. 2017;35(19):2173–83. https://​doi.​org/​10.​1200/​jco.​2016.​70.​5301.
54.
55.
56.
Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice - use of the distress thermometer. Cancer. 2008;113(4):870–8.CrossRefPubMed
57.
Boyes A, D'Este C, Carey M, Lecathelinais C, Girgis A. How does the distress thermometer compare to the hospital anxiety and depression scale for detecting possible cases of psychological morbidity among cancer survivors? Support Cancer Care. 2013;21(1):119–27.CrossRef
58.
Admiraal JM, Reyners AK, Hoekstra-Weebers JE. Do cancer and treatment type affect distress? Psycho-Oncology. 2013;22(8):1766–73.CrossRefPubMed
59.
Derogatis L, Lopez M. Brief symptom inventory 18: administration, scoring and procedures manual. Minneapolis: National Computer Systems; 2000.
60.
Zabora J, Brintzenhofszoc K, Jacobsen P, Curbow B, PIantadosi S, Hooker C, Owens A, Deregatis L. A new psychosocial screening instrument for use with cancer patients. Psychosomatics. 2001;42:241–6.CrossRefPubMed
61.
Schauenburg H, Strack M. Measuring psychotherapeutic change with the symptom checklist SCL90 R. Psychother Psychosom. 1999;68:199–206.CrossRefPubMed
62.
Aaronson N, Ahmedzai A, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, et al. The European Organization for Research and Treatment of cancer QLQ-C30. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
63.
Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The study group on quality of life of the EORTC and the symptom control and quality of life committees of the NCI of Canada clinical trials group. Qual Life Res. 1997;6(2):103–8.CrossRefPubMed
64.
Sprangers MAG, Te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur J Cancer. 1999;35:238–47.CrossRefPubMed
65.
Vercoulen JHMM, Alberts M, Bleijenberg G. De checklist individual strength (cis). Gedragstherapie. 1999;32:131–6.
66.
Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JM, Van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994;38:383–292.CrossRefPubMed
67.
Beurskens AJ, Bultmann U, Kant I, Vercoulen JHMM, Bleijenberg G, Swaen GM. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med. 2000;57:353–7.CrossRefPubMedCentralPubMed
68.
Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res. 2004;56:157–70.CrossRefPubMed
69.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed
70.
Norton S, Cosco T, Doyle F, Done J, Sacker A. The hospital anxiety and depression scale: a meta confirmatory factor analysis. J Psychosom Res. 2013;74(1):74–81.CrossRefPubMed
71.
Alexander S, Palmer C, Stone PC. Evaluation of screening instruments for depression and anxiety in breast cancer survivors. Breast Cancer Res Treat. 2010;122(2):573–8.CrossRefPubMed
72.
Annunziata MA, Muzzatti B, Altoe G. Defining hospital anxiety and depression scale (hads) structure by confirmatory factor analysis: a contribution to validation for oncological settings. Ann Oncol. 2011;22:2330–3.CrossRefPubMed
73.
Vodermaier A, Millman RD. Accuracy of the hospital anxiety and depression scale as a screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2011;19(12):1899–908.CrossRefPubMed
74.
Douma KFL, Aaronson NK, Vasen HFA, Bleiker EMA. Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology. 2008;17(8):737–45.CrossRefPubMed
75.
Custers JAE, van den Berg SW, van Laarhoven HWM, Bleiker EMA, Gielissen MFM, Prins JB. Cancer worry scale as instrument for detecting fear of recurrence in breast cancer survivors. Cancer Nurs. 2014;37(1):44–50.CrossRef
76.
Joseph S. Psychometric evaluation of Horowitz's impact of event scale: a review. J Trauma Stress. 2000;13(1):101–13.CrossRefPubMed
77.
Creamer M, Bell R, Failla S. Psychometric properties of the impact of event scale - revised. Behav Res Ther. 2003;41(12):1489–96.CrossRefPubMed
78.
van der Ploeg E, Mooren TT, Kleber RJ, van der Velden PG, Brom D. Construct validation of the Dutch version of the impact of event scale. Psychol Assess. 2004;16(1):16–26.CrossRefPubMed
79.
Gielissen MFM, Verhage CAHH, Blijenberg G. Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer. 2007;97(5):612–8.CrossRefPubMedCentralPubMed
80.
Servaes P, Verhagen S, Blijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol. 2002;13(4):589–98.CrossRefPubMed
81.
Bouwmans CAM, de Jong K, Timman R, Zijlstra-Vlasveld MC, Feltz-Cornelis CMVD, Tan SS, Hakkaart-van Roijen L. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv Res. 2013;13(1):1095–108.CrossRef
82.
83.
84.
Van den Berg SW, Peters EJ, Kraaijeveld JF, Gielissen MFM, Prins JB. Usage of a generic self-management intervention for breast cancer survivors: substudy analysis of the BREATH trial. J Med Internet Res. 2013;15(8):e170.CrossRefPubMedCentralPubMed
85.
van Scheppingen C, Schroevers MJ, Pool G, Smink A, Mul VE, Coyne JC, Sanderman R. Is implementing screening for distress an efficient means to recruit patients to a psychological intervention trial? Psycho-Oncology. 2014;23(5):516–23.CrossRefPubMed
86.
van Scheppingen C, Schroevers MJ, Smink A, van der Linden YM, Mul VE, Langendijk JA, Coyne JC, Sanderman R. Does screening for distress efficiently uncover meetable unmet needs in cancer patients? Psycho-Oncology. 2011;20(6):655–63.CrossRefPubMed
87.
Yardley L, Morrison L, Bradbury K, Muller I. The person-based approach to intervention development: application to digital health-related behavior change interventions. J Med Internet Res. 2015;17(1):e30.CrossRefPubMedCentralPubMed
88.
Crawford MJ, Rutter D, Manley C, Weaver T, Bhui K, Fulop N, Tyrer P. Systematic review of involving patients in the planning and development of health care. BMJ. 2002;325(7375):1263.CrossRefPubMedCentralPubMed
Metadata
Title
Study protocol of the CORRECT multicenter trial: the efficacy of blended cognitive behavioral therapy for reducing psychological distress in colorectal cancer survivors
Authors
L. Leermakers
S. Döking
B. Thewes
A. M. J. Braamse
M. F. M. Gielissen
J. H. W. de Wilt
E. H. Collette
J. Dekker
J. B. Prins
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4645-6

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov

Case report

Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

Research article

Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data

Research article

Knowledge towards cervical cancer prevention and screening practices among women who attended reproductive and child health clinic at Magu district hospital, Lake Zone Tanzania: a cross-sectional study

Research article

Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm

Research article

Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits